Search
Parecoxib
go.drugbank.com/drugs/DB08439ApprovedInvestigationalA letter of non-approval for parecoxib was issued by the FDA in 2005. … It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx).
Synonyms: N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamideProducts: DYNASTAT (POWDER FOR SOLUTION FOR INJECTION 40 MG/2ML), DYNASTAT ® 40 MG POLVO LIOFILIZADO PARA SOLUCION INYECTABLERifabutin
go.drugbank.com/drugs/DB00615ApprovedInvestigationalA broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
Synonyms: 4-N-isobutylspiropiperidylrifamycin S, 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin SProducts: Mycobutin 150 mg - Kapseln, RIFBUTIN® 150 MG CAPSULASCalcium chloride
go.drugbank.com/drugs/DB01164ApprovedInvestigationalCalcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. … It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in cement.
International brands: LiquiCal-D 400Mixtures: SOLUCION DP PISA 2.5%(MODIFICADA EN MAGNESIO Y LACTATO), POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 2000 MLRimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … It was rejected for approval for use in the United States.
Products: ACOMPLIA ® COMPRIMIDOS RECUBIERTOS20 MGCangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalCangrelor was approved by the FDA in June 2015 for intravenous application. … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset
Products: KENGREXAL 50 MG ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 10 ADETHemoglobin glutamer-250 (bovine)
go.drugbank.com/drugs/DB19235InvestigationalHemoglobin glutamer-250 (bovine) is under investigation in clinical trial NCT00300040 (Safety/feasibility Study of HBOC-201 in Amputation At/below Knee From Critical Lower Limb Ischemia).
Synonyms: Hemoglobin-based oxygen carrier 201 is purified, glutaraldehyde-polymerized, bovine hemoglobin, mw 250000Benfotiamine
go.drugbank.com/drugs/DB11748ApprovedInvestigationalWithdrawnBenfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.
Categories: Compounds used in a research, industrial, or household settingProducts: NEVRALON B 300 MG FİLM KAPLI TABLET, 30 TABLET, B-Gamma 300 mg Film Kaplı Tablet (30 adet)Clofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawnIt was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. … [A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis
Products: CLOFZIMIN® 100 MG, Fazim 50 mg CapsuleDiethylstilbestrol
go.drugbank.com/drugs/DB00255ApprovedWithdrawnA synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. … (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.[L43942]
Synonyms: (E)-3,4-bis(4-hydroxyphenyl)-3-hexene, α,α'-diethyl-(E)-4,4'-stilbenediolProducts: Stilbestrol Tablets 1.0 mg, Stilbestrol Tablets 0.1 mgMidostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalIt was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Synonyms: 4'-N-benzoylstaurosporineProducts: RYDAPT (25 MG SOFT CAPSULES), RYDAPT 25 MG YUMUŞAK KAPSÜL, 112 ADET